In early childhood, she developed an unusual rash on her back. A dermatologist considered contact dermatitis. Years later, a mole on the external pubic area was biopsied and found to be a benign compound nevus.
In 2025, a rash developed on the breasts and, during the first episode, on the legs. It was initially thought to be eczema and was later considered possibly impetigo. Antibiotic treatment and a topical cream improved it, but the breast rash subsequently returned. Breast imaging and ultrasound were performed because clinicians wanted to exclude Paget disease; the workup did not establish Paget disease.
She also experiences intermittent itching of the breasts, the inner elbows, and the hands. A visible rash is usually present only on the breasts, not on the elbows or hands.
Her vaccinations have been kept up to date. Her family says she is generally not sick often and has not shown a consistent pattern of prolonged systemic worsening after common infections.
Medication and treatment responses
Her medication history reflects years of trying to improve seizures, attention, emotional regulation, and menstrual distress:
Ethosuximide was started after the absence-epilepsy diagnosis in 2016. Visible absence events improved, but EEG spikes or discharges continued, and the family remained concerned about incomplete control.
Lamotrigine replaced ethosuximide in November 2020. The family has not observed further breakthrough absence seizures, and the EEG discharges reportedly became shorter, although annual EEGs remain abnormal. The late-teen dose was reported as 100 mg twice daily. Missing a dose can be followed by severe dysregulation, making consistent administration especially important.
Stimulants for attention included Vyvanse, Focalin XR, Ritalin or methylphenidate, and Adderall. They did not produce a meaningful enough improvement in attention to justify the side effects. Facial, mouth, and neck movements developed, including an unusual swallowing-like motion in which she extended her neck. The movements resolved after the stimulant was stopped, and the family did not continue stimulant treatment.
Fluoxetine and guanfacine were started through psychiatry in 2018. Guanfacine was tapered first beginning in 2024, and fluoxetine was stopped in October 2025. The family did not see adverse effects from discontinuation and found it difficult to determine how much either medication had helped.
Menstrual suppression progressed from injections to an IUD and then to a daily progestin-only pill.
Skin treatment with an antibiotic and topical cream improved the 2025 rash, although the breast symptoms later recurred.
No unusual response to anesthesia, procedural sedation, acetaminophen, or antibiotics has been reported.